M
Martin H. Cohen
Researcher at United States Department of Veterans Affairs
Publications - 140
Citations - 8199
Martin H. Cohen is an academic researcher from United States Department of Veterans Affairs. The author has contributed to research in topics: Combination chemotherapy & Cancer. The author has an hindex of 45, co-authored 138 publications receiving 7916 citations. Previous affiliations of Martin H. Cohen include SUNY Downstate Medical Center & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Prognostic effect of weight loss prior tochemotherapy in cancer patients
William D. Dewys,Colin B. Begg,Philip T. Lavin,Pierre R. Band,John M. Bennett,Joseph R. Bertino,Martin H. Cohen,Harold O. Douglass,Paul F. Engstrom,Ediz Z. Ezdinli,John Horton,Gerhard J. Johnson,Charles G. Moertel,Martin M. Oken,Charles P. Perlia,Charles Rosenbaum,Murray N. Silverstein,Roland T. Skeel,Robert W. Sponzo,Douglass C. Tormey +19 more
TL;DR: The prognostic effect of weight loss prior to chemotherapy was analyzed using data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group and increased with increasing number of anatomic sites involved with metastases, but within categories of Anatomic involvement, weight loss was associated with decreased median survival.
Journal ArticleDOI
CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival.
John L. Nugent,Paul A. Bunn,Mary J. Matthews,Daniel C. Ihde,Martin H. Cohen,Adi F. Gazdar,John D. Minna +6 more
TL;DR: Prophylactic therapy appears necessary at present to prevent the morbidity associated with these metastases and, as further improvements in systemic therapy evolve, CNS prophylaxis may also be required for “cure” of patients with small cell lung cancer.
Journal Article
Approval Summary Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors
Ramzi Dagher,Martin H. Cohen,Gene M. Williams,Mark D. Rothmann,Jogarao V. S. Gobburu,Gabriel Robbie,Atiqur Rahman,Gang Chen,Ann Staten,Donna Griebel,Richard Pazdur +10 more
TL;DR: The pharmacokinetics of imatinib in GIST patients were similar to those of chronic myelogenous leukemia patients and the basis for marketing approval, and postmarketing commitments by the drug's manufacturer are discussed.
Journal ArticleDOI
The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes
Peter A. Radice,Mary J. Matthews,Daniel C. Ihde,Adi F. Gazdar,Desmond N. Carney,Paul A. Bunn,Martin H. Cohen,Byron E. Fossieck,Robert W. Makuch,John D. Minna +9 more
TL;DR: Mixed histology small cell/large cell carcinoma represents a distinct pathologic variant of small cell carcinomas of the lung, associated with lower response rates and shorter survival than the ‘pure’ small cell subtypes.
Journal Article
Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Martin H. Cohen,Daniel C. Ihde,Paul A. Bunn,Byron E. Fossieck,Mary J. Matthews,Stanley E. Shackney,A Johnston-Early,Robert W. Makuch,John D. Minna +8 more
TL;DR: Sequential use of non-cross-resistant drug combinations represents one method for increasing the CR rate and prolong survival in small cell bronchogenic carcinoma patients.